No connection

Search Results

ACON vs ISPC

ACON
Aclarion, Inc.
BEARISH
Price
$3.33
Market Cap
$3.5M
Sector
Healthcare
AI Confidence
92%
ISPC
iSpecimen Inc.
BEARISH
Price
$0.13
Market Cap
$3.8M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ACON
--
ISPC
--
Forward P/E
ACON
-0.24
ISPC
-0.16
P/B Ratio
ACON
0.16
ISPC
0.41
P/S Ratio
ACON
52.03
ISPC
1.97
EV/EBITDA
ACON
1.38
ISPC
0.32

Profitability

Gross Margin
ACON
-7.83%
ISPC
1.25%
Operating Margin
ACON
-9666.16%
ISPC
-5192.87%
Profit Margin
ACON
0.0%
ISPC
0.0%
ROE
ACON
-97.72%
ISPC
-327.77%
ROA
ACON
-52.37%
ISPC
-59.44%

Growth

Revenue Growth
ACON
31.5%
ISPC
-96.5%
Earnings Growth
ACON
--
ISPC
--

Financial Health

Debt/Equity
ACON
--
ISPC
0.09
Current Ratio
ACON
17.01
ISPC
1.12
Quick Ratio
ACON
16.31
ISPC
1.11

Dividends

Dividend Yield
ACON
--
ISPC
--
Payout Ratio
ACON
0.0%
ISPC
0.0%

AI Verdict

ACON BEARISH

ACON's deterministic health scores are severely compromised: the Piotroski F-Score of 1/9 signals extreme financial distress, and the absence of an Altman Z-Score (with negative profitability and liquidity anomalies) raises serious bankruptcy concerns. Despite a 31.5% YoY revenue growth, the company exhibits catastrophic profitability—negative gross, operating, and ROE margins—indicating fundamental operational failure. The stock trades at a price/sales of 52.03, vastly exceeding peers and suggesting extreme overvaluation relative to earnings. Analysts' target price of $23.00 is not supported by fundamentals, and insider activity remains neutral with no recent trades. The 5-year price decline of 100% underscores deep investor skepticism.

Strengths
31.5% year-over-year revenue growth indicates top-line expansion
High current and quick ratios (17.01 and 16.31) suggest strong short-term liquidity
Recent 1-month price increase (+22.9%) shows short-term momentum
Risks
Piotroski F-Score of 1/9 indicates severe financial deterioration and poor operational health
Negative operating margin (-9666.16%) and ROE (-97.72%) reflect systemic profitability collapse
Price/Sales of 52.03 is unsustainable and far exceeds peer averages (avg: ~185.39 P/E, but negative margins suggest no valid comparison)
ISPC BEARISH

The company is in severe financial distress, evidenced by a critical Piotroski F-Score of 1/9 and a total absence of a viable Altman Z-Score. Revenue has collapsed by 96.50% year-over-year, while operating margins have plummeted to -5192.87%, indicating a complete breakdown of the business model. With a 5-year price decline of 99.9% and a technical trend score of 0/100, the stock is in a terminal bearish phase. Despite a low debt-to-equity ratio, the lack of top-line growth and extreme losses make the equity highly speculative and high-risk.

Strengths
Low Debt/Equity ratio (0.09) suggests minimal long-term debt burden
Current Ratio of 1.12 indicates marginal short-term liquidity
Trading at a discount to book value (P/B 0.41)
Risks
Catastrophic revenue decline of -96.50% YoY
Extreme operational inefficiency with -5192.87% operating margin
Severe financial instability indicated by Piotroski F-Score of 1/9

Compare Another Pair

ACON vs ISPC: Head-to-Head Comparison

This page compares Aclarion, Inc. (ACON) and iSpecimen Inc. (ISPC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile